 Home > Active Ingredient News > Infection > Lancet: The new crown vaccine BNT162b2 is effective in preventing delta variant infections as high as 93%!

Lancet: The new crown vaccine BNT162b2 is effective in preventing delta variant infections as high as 93%!

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

october 21

4.6 years ago

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

To date, the effectiveness of the vaccine has not been studied to distinguish δ (delta, B.
1.
617.
2) variants and potential immunity weakened the crown observed for the new virus (SARS-CoV-2) infection affect the validity of reduced terms
.

Immune infection

Recently, " The Lancet ," a retrospective cohort study on newly published, assessed the new crown vaccine BNT162b2 (tozinameran, Pfizer-BioNTech) of the new crown viral infections and the new crown pneumonia overall and mutation-specific related hospitalized patients from vaccinated since Effectiveness
.

"The Lancet " Lancet New Coronary Pneumonia

In the study, the researchers analyzed the electronic health records of members (≥12 years old) of California health care organizations to evaluate the effectiveness of the BNT162b2 vaccine in preventing new coronavirus infections and new coronary pneumonia-related hospitalizations
.
Evaluation indicators include the result of a positive PCR test for the new coronavirus and hospitalization related to new coronary pneumonia

prevention

Effectiveness of BNT162b2 vaccine to prevent new coronavirus infection and related hospitalizations

From December 14, 2020 to August 8, 2021, 4,920,549 individuals were screened for conditions, and 3,436,957 subjects were finally included (median age 45 years; 1,799,395 men [52.
4%])
.
For individuals who have completed two doses of vaccination, the effective rate of BNT162b2 vaccine to prevent new coronavirus infection is 73% (95% CI 72-74), and the effective rate to prevent new coronary pneumonia-related hospitalization is 90% (89-92)

Screening For individuals who have completed two doses of vaccination, the BNT162b2 vaccine has an effective rate of 73% (95% CI 72–74) for preventing new coronavirus infections, and an effective rate of 90% (89–92) for preventing new coronary pneumonia-related hospitalizations

Effectiveness of BNT162b2 vaccine against different variants

Among subjects infected with the new coronavirus, the effective rate of preventing δ variant infection within the first month after completing vaccination was as high as 93% (95% CI 85-97), but it dropped to 53% after 4 months (39-65)

The BNT162b2 vaccine has a high rate of preventing hospitalization of new coronary pneumonia within 6 months after complete vaccination, even in the face of the widespread spread of δ variants .

Original source:

Sara Y Tartof, et al.

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.

Effectiveness of mRNA BNT162b2 COVID-19 Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.